NT5C1B-RDH14: A Potential Drug Target and Biomarker (G100526794)

Target Name: NT5C1B-RDH14

NCBI ID: G100526794

NT5C1B-RDH14

NT5C1B-RDH14: A Potential Drug Target and Biomarker

The nervous system is a complex and dynamic system that is responsible for controlling and coordinating all the body's functions. It is made up of a vast array of neurons and their associated synapses, which communicate with each other through various chemical and electrical signals. One of the key molecules that are involved in these signals is neurotransmitter HTTP (hypersensitive sodium channel), which is responsible for transmitting signals between neurons.

NT5C1B-RDH14 is a protein that is expressed in the nervous system and has been shown to play a role in the regulation of neurotransmitter release. It is a member of the馃槈 family of transmembrane proteins, which means that it spans the cell membrane and is involved in various signaling processes.

Potential Drug Target

NT5C1B-RDH14 has been identified as a potential drug target due to its involvement in neurotransmitter regulation. Studies have shown that NT5C1B-RDH14 is involved in the regulation of the release of several neurotransmitters, including HTTP, which is important for communication between neurons.

One of the potential benefits of targeting NT5C1B-RDH14 is its potential to treat various neurological and psychiatric disorders, such as depression, anxiety, and schizophrenia. These disorders are often characterized by disruptions in the normal functioning of the nervous system, which can lead to symptoms such as mood changes, hallucinations, and abnormal behaviors.

In addition to its potential as a drug target, NT5C1B-RDH14 has also been shown to be a potential biomarker for several neurological disorders. For example, studies have shown that NT5C1B-RDH14 levels are often elevated in individuals with depression and anxiety, which suggests that it may be a useful diagnostic tool for these disorders.

Biomarker Potential

NT5C1B-RDH14 has also been shown to be a potential biomarker for several other neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These disorders are characterized by progressive muscle stiffness, tremors, and other motor symptoms, as well as cognitive impairments.

One of the key challenges in the diagnosis and treatment of these disorders is the lack of reliable biomarkers that can be used to identify the early stages of disease. NT5C1B-RDH14 may be such a biomarker, as its levels have been shown to be elevated in individuals with Alzheimer's disease and Parkinson's disease, which suggests that it may be a useful diagnostic tool for these disorders.

Another Potential Drug Target

NT5C1B-RDH14 may also be a potential drug target due to its involvement in the regulation of neurotransmitter release. Studies have shown that NT5C1B-RDH14 is involved in the regulation of the release of several neurotransmitters, including HTTP, which is important for communication between neurons. This suggests that targeting NT5C1B-RDH14 may be a useful approach for treating disorders that are characterized by disruptions in neurotransmitter regulation.

Conclusion

In conclusion, NT5C1B-RDH14 is a protein that is involved in the regulation of neurotransmitter release and has been identified as a potential drug target and biomarker for several neurological disorders. Further research is needed to fully understand the role of NT5C1B-RDH14 in the nervous system and its potential as a drug and biomarker.

Protein Name: NT5C1B-RDH14 Readthrough

Functions: Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, AMP is the major substrate

The "NT5C1B-RDH14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NT5C1B-RDH14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets